1-ethyl-4-(4-nitrophenyl)piperidine | 943189-39-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-ethyl-4-(4-nitrophenyl)piperidine
• CAS: 943189-39-7
• 化学式: C₁₃H₁₈N₂O₂
• 分子量: 234.298
• InChiKey: JQFDATOQVHFNQL-UHFFFAOYSA-N

物化性质

• 沸点：
  349.8±42.0 °C(Predicted)
• 密度：
  1.109±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  49.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-ethyl-4-(4-nitrophenyl)piperidine 在 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 19.0h， 生成 N-[4-(1-ethylpiperidin-4-yl)phenyl]-N'-methyl-pyrimidine-4,6-diamine
  参考文献：
  名称：

  Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

  摘要：

  A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. These results support the potential therapeutic use of 1h as a new anticancer agent.

  DOI：

  10.1021/jm2006222
• 作为产物：
  描述：

  1-Ethyl-4-phenyl-piperidin 在 硫酸 、 硝酸 作用下， 以70.9%的产率得到1-ethyl-4-(4-nitrophenyl)piperidine
  参考文献：
  名称：

  FGFR抑制剂化合物及其用途

  摘要：

  本申请涉及FGFR抑制剂化合物及其用途。具体地，本申请公开了如式(I)所示的化合物、或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体或异构体混合物、或其药学上可接受的盐、或其前药、或其代谢物。本申请还涉及所述化合物在医学方面的应用。

  公开号：

  CN113666911A

文献信息

• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Pharmacyclics, Inc.

  公开号：US20150158865A1

  公开（公告）日：2015-06-11

  Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了布鲁顿酪氨酸激酶（Btk）的可逆和不可逆抑制剂。还披露了包括这些化合物的药物组合物。描述了使用Btk抑制剂的方法，单独或与其他治疗剂联合用于治疗自身免疫疾病或症状、异种免疫疾病或症状、包括淋巴瘤在内的癌症，以及炎症性疾病或症状。
• Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors
  申请人：Bold Guido

  公开号：US20080312248A1

  公开（公告）日：2008-12-18

  The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

  本发明涉及公式IA的杂环芳基基脲化合物，其中基团和符号的含义如本文所定义，这些化合物在蛋白激酶依赖性疾病的治疗中的使用；含有上述杂环芳基基脲化合物的制药制剂；制备这些新化合物的方法以及使用这些杂环芳基基脲化合物的治疗方法。
• Pyrimidinyl aryl urea derivatives being FGF inhibitors
  申请人：Novartis AG

  公开号：US08293746B2

  公开（公告）日：2012-10-23

  The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

  本发明涉及公式IA的杂环芳基基脲，其中基团和符号的含义如此处所定义，以及在蛋白激酶依赖性疾病治疗中使用这种化合物；包括含有这种杂环芳基基脲的制药制剂，制造这种新化合物的工艺以及使用这种杂环芳基基脲的治疗方法。
• Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors
  申请人：Novartis AG

  公开号：US20130030171A1

  公开（公告）日：2013-01-31

  The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

  本发明涉及式子IA的杂环芳基芳基脲，其中基团和符号的含义在此定义，这些化合物在蛋白激酶依赖性疾病的治疗中的使用；制备包括所述杂环芳基芳基脲的药物制剂；制造这种新型化合物的过程以及包括使用这种杂环芳基芳基脲的治疗方法。
• Pyrirnidinyl aryl urea derivatives being FGF inhibitors
  申请人：Novartis AG

  公开号：US08759517B2

  公开（公告）日：2014-06-24

  The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

  本发明涉及公式IA的杂环芳基基脲化合物，其中基团和符号的含义如本文所定义，在蛋白激酶依赖性疾病的治疗中使用这种化合物；包括含有这些杂环芳基基脲化合物的制药制剂，制造这种新型化合物的方法和使用这种杂环芳基基脲化合物的治疗方法。